InvaGen Pharmaceuticals recalls Vigabatrin oral solution due to risk of powder leaking from pouches. This medication is prescription-only and may cause ineffective treatment if powder leaks.
“InvaGen Vigabatrin Oral Solution Recall: Leaking Powder Hazard.” GovInfoNow, updated September 23, 2026. https://govinfonow.com/recall/32944-invagen-vigabatrin-oral-solution-recall-leaking-powder-hazard. Based on FDA recall #D-0220-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0220-2024%22&limit=1).
InvaGen Pharmaceuticals, Inc. voluntarily recalled Vigabatrin for Oral Solution on Nov. 17, 2023, after the FDA announced the Class I recall due to defective containers that may allow powder to leak. The Food and Drug Administration issued the recall notice under agency number D-0220-2024.
How to tell if you have it
Brand: InvaGen
Product: Vigabatrin for Oral Solution, USP 500 mg per packet, 50 packets per box
NDC: 69097-964-53
Lot #: NB301030
Exp. Date: 03/31/2025
Quantity: 1240 boxes
The hazard
The recall addresses defective containers in which the powder may leak out of the pouch. The FDA classified this as a Class I recall, indicating a high risk of serious adverse health consequences or death.
Context
GovInfoNow's records show InvaGen Pharmaceuticals, Inc. has had 7 other recalls on record since March 5, 2018. Other recent recalls of similar products include Mallinckrodt Acthar Gel 5mL Vial Recall (Aug. 6, 2026), B Braun Dextrose Injection Recall (April 2, 2026), and Radnostix Sodium Iodide Solution Recall (Jan. 26, 2026).
How to tell if you have this one
Check for Vigabatrin oral solution packets labeled '500 mg per packet, 50 packets per box' manufactured by InvaGen Pharmaceuticals. The product was made in Hauppauge, NY with lot number NB301030 and expires March 31, 2025.
Brand
InvaGen
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Medication
Verify the product label matches the description: Vigabatrin oral solution, 500 mg per packet, 50 packets per box, manufactured by InvaGen Pharmaceuticals.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide within the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 2 months after the firm started it.
1Firm started the recall
2FDA classified it Class I
3Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0220-2024 (November 17, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0220-2024 to see it in context.
Plain-language summary written by qwen3:4b on September 23, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.